Klin Farmakol Farm. 2016;30(2):32-37 | DOI: 10.36290/far.2016.017

Symptomatic treatment of gouty arthritis

Hana Ciferská1, Lenka Petrů1, Jan Vachek2
1 Revmatologický ústav, Praha, a Revmatologická klinika 1. LF UK Praha
2 Klinika nefrologie, Všeobecná fakultní nemocnice a 1. LF UK Praha

Gouty arthritis belongs to the group of crystal-induced arthropathies and is among the most common inflammatory joint diseases

that is often associated with a wide range of metabolic diseases. Timely diagnosis and initiation of adequate treatment reduces

the duration of gouty attack. The gold standard is articular puncture, if technically feasible, with analysis of the articular aspirate

with demonstration of sodium urate crystals. If this is not feasible, diagnosis can be made based on the ACR (American College

of Rheumatology) classification criteria that are a combination of clinical symptoms and paraclinical examinations. The treatment

of chronic gout is associated with both preventing acute exacerbations and affecting uric acid levels as well as an effort to prevent

or reduce the formation of tophi and development of renal injury.

Keywords: gout, hyperuricaemia, uric acid, allopurinol, febuxostat, non-steroid anti-inflammatory drugs, colchicine, biological therapy

Published: September 19, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Ciferská H, Petrů L, Vachek J. Symptomatic treatment of gouty arthritis. Klin Farmakol Farm. 2016;30(2):32-37. doi: 10.36290/far.2016.017.
Download citation

References

  1. Schlesinger N. Diagnosis of gout: clinical, laboratory, and radiologic findings. Am J Manag Care. 2005; 11(15 Suppl): S443-50; quiz S465-8. Go to PubMed...
  2. Punzi L, Scanu A, Ramonda R, et al. Gout as autoinflammatory disease: new mechanisms for more appropriated treatment targets. Autoimmun Rev. 2012; 12(1): 66-71. Go to original source... Go to PubMed...
  3. Pavelka K. Diagnostika a terapie dny Vnitř lék 2015; 61(6): 517-526.
  4. Smith E, Hoy D, Cross M, et al. The global burden of gout: estimates from the Global Burden of Disease 2010 study. Ann Rheum Dis 2014; 73: 1470. Go to original source... Go to PubMed...
  5. Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum 2011; 63: 3136. Go to original source... Go to PubMed...
  6. Khanna D, Fitzgerald JD, Khanna PP, et. al American College of Rheumatology 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia.Arthritis Care Res (Hoboken). 2012; 64(10): 1431-1446. Go to original source... Go to PubMed...
  7. Sivera F, Andrés M, Carmona L, et al. Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. Ann Rheum Dis. 2014; 73(2): 328-335. Go to original source... Go to PubMed...
  8. Janssens HJ, Fransen J, van de Lisdonk EH, et al. A diagnostic rule for acute gouty arthritis in primary care without joint fluid analysis. Arch Intern Med. 2010; 170(13): 1120. Go to original source... Go to PubMed...
  9. Cronstein BN, Sunkureddi P. Mechanistic aspects of inflammation and clinical management of inflammation in acute gouty arthritis. J Clin Rheumatol. 2013; 19(1): 19-29. Go to original source... Go to PubMed...
  10. Wechalekar MD, Vinik O, Moi JH, et al. The efficacy and safety of treatments for acute gout: results from a series of systematic literature reviews including Cochrane reviews on intraarticular glucocorticoids, colchicine, nonsteroidal antiinflammatory drugs, and interleukin-1 inhibitors. J Rheumatol Suppl. 2014; 92: 15-25. Go to original source... Go to PubMed...
  11. Sunkureddi P. Gouty arthritis: understanding the disease state and management options in primary care. Adv Ther. 2011; 28(9): 748-760. Go to original source... Go to PubMed...
  12. Neogi T, Jansen TL, Dalbeth N, et al. 2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2015; 74(10): 1789-1798. Go to original source... Go to PubMed...
  13. van Durme CM, Wechalekar MD, Buchbinder R, et al. Non-steroidal anti-inflammatory drugs for acute gout. Cochrane Database Syst Rev. 2014; 9: CD010120. Go to original source... Go to PubMed...
  14. Sutaria S, Katbamna R, Underwood M. Effectiveness of interventions for the treatment of acute and prevention of recurrent gout-a systematic review. Rheumatology (Oxford). 2006; 45(11): 1422. Go to original source... Go to PubMed...
  15. Pavelka K. Doporučení České revmatologické společnosti pro léčbu dnavé artritidy. Čes. Revmatol. 2012; 20(2): p. 82-92.
  16. Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006; 65: 1312. Go to original source... Go to PubMed...
  17. Svačina Š, et al. Klinická dietologie. Grada Publishing a. s., 2008; 190-191.
  18. Moi JH, Sriranganathan MK, Falzon L, et al. Lifestyle Interventions for the Treatment of Gout: A Summary of 2 Cochrane Systematic Reviews. J Rheumatol Suppl. 2014; 92: 26-32. Go to original source... Go to PubMed...
  19. Jutkowitz E, Choi HK, Pizzi LT, Kuntz KM. Cost-effectiveness of allopurinol and febuxostat for the management of gout. Ann Intern Med 2014; 161: 617. Go to original source... Go to PubMed...
  20. Roch-Ramel F, Guisan B, Diezi J. Effects of uricosuric and antiuricosuric agents on urate transport in human brush-border membrane vesicles.J Pharmacol Exp Ther. 1997; 280(2): 839-845.




Clinical Pharmacology and Pharmacy

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.